Cargando…
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2965882/ http://dx.doi.org/10.1038/sj.bjc.6605921 |
| _version_ | 1782189554736824320 |
|---|---|
| author | Dawson, S-J Makretsov, N Blows, F M Driver, K E Provenzano, E Le Quesne, J Baglietto, L Severi, G Giles, G G McLean, C A Callagy, G Green, A R Ellis, I Gelmon, K Turashvili, G Leung, S Aparicio, S Huntsman, D Caldas, C Pharoah, P |
| author_facet | Dawson, S-J Makretsov, N Blows, F M Driver, K E Provenzano, E Le Quesne, J Baglietto, L Severi, G Giles, G G McLean, C A Callagy, G Green, A R Ellis, I Gelmon, K Turashvili, G Leung, S Aparicio, S Huntsman, D Caldas, C Pharoah, P |
| author_sort | Dawson, S-J |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-2965882 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2010 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-29658822010-11-02 BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received Dawson, S-J Makretsov, N Blows, F M Driver, K E Provenzano, E Le Quesne, J Baglietto, L Severi, G Giles, G G McLean, C A Callagy, G Green, A R Ellis, I Gelmon, K Turashvili, G Leung, S Aparicio, S Huntsman, D Caldas, C Pharoah, P Br J Cancer Corrigendum Nature Publishing Group 2010-09-28 2010-09-28 /pmc/articles/PMC2965882/ http://dx.doi.org/10.1038/sj.bjc.6605921 Text en Copyright © 2010 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Corrigendum Dawson, S-J Makretsov, N Blows, F M Driver, K E Provenzano, E Le Quesne, J Baglietto, L Severi, G Giles, G G McLean, C A Callagy, G Green, A R Ellis, I Gelmon, K Turashvili, G Leung, S Aparicio, S Huntsman, D Caldas, C Pharoah, P BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received |
| title | BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received |
| title_full | BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received |
| title_fullStr | BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received |
| title_full_unstemmed | BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received |
| title_short | BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received |
| title_sort | bcl2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2965882/ http://dx.doi.org/10.1038/sj.bjc.6605921 |
| work_keys_str_mv | AT dawsonsj bcl2inbreastcancerafavourableprognosticmarkeracrossmolecularsubtypesandindependentofadjuvanttherapyreceived AT makretsovn bcl2inbreastcancerafavourableprognosticmarkeracrossmolecularsubtypesandindependentofadjuvanttherapyreceived AT blowsfm bcl2inbreastcancerafavourableprognosticmarkeracrossmolecularsubtypesandindependentofadjuvanttherapyreceived AT driverke bcl2inbreastcancerafavourableprognosticmarkeracrossmolecularsubtypesandindependentofadjuvanttherapyreceived AT provenzanoe bcl2inbreastcancerafavourableprognosticmarkeracrossmolecularsubtypesandindependentofadjuvanttherapyreceived AT lequesnej bcl2inbreastcancerafavourableprognosticmarkeracrossmolecularsubtypesandindependentofadjuvanttherapyreceived AT bagliettol bcl2inbreastcancerafavourableprognosticmarkeracrossmolecularsubtypesandindependentofadjuvanttherapyreceived AT severig bcl2inbreastcancerafavourableprognosticmarkeracrossmolecularsubtypesandindependentofadjuvanttherapyreceived AT gilesgg bcl2inbreastcancerafavourableprognosticmarkeracrossmolecularsubtypesandindependentofadjuvanttherapyreceived AT mcleanca bcl2inbreastcancerafavourableprognosticmarkeracrossmolecularsubtypesandindependentofadjuvanttherapyreceived AT callagyg bcl2inbreastcancerafavourableprognosticmarkeracrossmolecularsubtypesandindependentofadjuvanttherapyreceived AT greenar bcl2inbreastcancerafavourableprognosticmarkeracrossmolecularsubtypesandindependentofadjuvanttherapyreceived AT ellisi bcl2inbreastcancerafavourableprognosticmarkeracrossmolecularsubtypesandindependentofadjuvanttherapyreceived AT gelmonk bcl2inbreastcancerafavourableprognosticmarkeracrossmolecularsubtypesandindependentofadjuvanttherapyreceived AT turashvilig bcl2inbreastcancerafavourableprognosticmarkeracrossmolecularsubtypesandindependentofadjuvanttherapyreceived AT leungs bcl2inbreastcancerafavourableprognosticmarkeracrossmolecularsubtypesandindependentofadjuvanttherapyreceived AT aparicios bcl2inbreastcancerafavourableprognosticmarkeracrossmolecularsubtypesandindependentofadjuvanttherapyreceived AT huntsmand bcl2inbreastcancerafavourableprognosticmarkeracrossmolecularsubtypesandindependentofadjuvanttherapyreceived AT caldasc bcl2inbreastcancerafavourableprognosticmarkeracrossmolecularsubtypesandindependentofadjuvanttherapyreceived AT pharoahp bcl2inbreastcancerafavourableprognosticmarkeracrossmolecularsubtypesandindependentofadjuvanttherapyreceived |